Insilico Medicine plans to push its computer-designed drug into pivotal clinical trials after a phase 2a study demonstrated ...

Boehringer Ingelheim says it is on track to launch 25 ... of its recent CKD approval as well as pulmonary fibrosis therapy Ofev (nintedanib). According to a Reuters report, the company has now ...

Boehringer Ingelheim has announced an increase in sales ... Boehringer also has a new blockbuster – the respiratory drug Ofev, which is approved for idiopathic pulmonary fibrosis and increased ...

More than 530 million people worldwide living with diabetes are at risk for developing diabetic retinal disease (DRD), the leading cause of ...